ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Viral receptors are essential host factors that determine the tropism of oncolytic viruses, and contribute to their selective targeting of cancer cells. In this study, a membrane protein-targeted CRISPR-Cas9 screen is conducted and identify transmembrane protein adipocyte-associated 1 (TPRA1) as a novel receptor for oncolytic virus M1(OVM), a promising oncolytic virus currently under clinical investigation. Mechanistically, TPRA1 facilitates OVM infection by promoting both viral attachment and internalization. Extracellular region of TPRA1 directly binds OVM particles via glycosylation, while its cytoplasmic tail mediates virus endocytosis, collectively enabling efficient viral entry and cancer cell lysis. Importantly, TPRA1 expression in cell lines, mouse models, and patient-derived tumor samples are positively correlated with their respective sensitivity to OVM, and TPRA1 is upregulated in a high proportion of tumors compared to adjacent normal tissues, highlighting its potential as a therapeutic response biomarker. Furthermore, TPRA1 also promotes the entry of Semliki Forest Virus, suggesting its conserved role in alphavirus infection. Together, these findings establish TPRA1 as both a mechanistic determinant of OVM tropism and a biomarker to guide patient selection in clinical trials of OVM-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.